XFOR icon

X4 Pharmaceuticals

4.33 USD
-0.02
0.46%
Updated Apr 30, 3:54 PM EDT
1 day
-0.46%
5 days
-17.37%
1 month
-38.93%
3 months
-78.20%
6 months
-72.19%
Year to date
-80.81%
1 year
-87.11%
5 years
-98.45%
10 years
-99.83%
 

About: X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Employees: 143

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

310% more call options, than puts

Call options by funds: $550K | Put options by funds: $134K

9% more capital invested

Capital invested by funds: $67.3M [Q3] → $73.2M (+$5.92M) [Q4]

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

1.17% less ownership

Funds ownership: 59.7% [Q3] → 58.53% (-1.17%) [Q4]

8% less funds holding

Funds holding: 98 [Q3] → 90 (-8) [Q4]

29% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 21

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$45
939%
upside
Avg. target
$68
1,459%
upside
High target
$90
1,979%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
28% 1-year accuracy
54 / 192 met price target
939%upside
$45
Buy
Reiterated
27 Mar 2025
Cantor Fitzgerald
Kristen Kluska
24% 1-year accuracy
24 / 101 met price target
1,979%upside
$90
Overweight
Reiterated
26 Mar 2025

Financial journalist opinion

Based on 4 articles about XFOR published over the past 30 days

Positive
Benzinga
2 days ago
Top 3 Health Care Stocks That May Rocket Higher In April
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks That May Rocket Higher In April
Neutral
GlobeNewsWire
6 days ago
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025.
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
Neutral
GlobeNewsWire
6 days ago
X4 Pharmaceuticals Announces Reverse Stock Split
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its board of directors has determined to effect a one-for-thirty reverse stock split of the company's Common Stock, par value $0.001 per share. The reverse stock split will take effect at 12:01 a.m.
X4 Pharmaceuticals Announces Reverse Stock Split
Neutral
GlobeNewsWire
6 days ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 450,471 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Seeking Alpha
1 month ago
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Stephen Willey - Stifel Ed Tenthoff - Piper Sandler Ayan Hussein - Cantor Fitzgerald Doug MacPherson - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites;  full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Neutral
GlobeNewsWire
1 month ago
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 and provide corporate updates on Tuesday, March 25, 2025.
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
Neutral
GlobeNewsWire
2 months ago
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Neutral
GlobeNewsWire
2 months ago
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on track for mid-2025
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
Neutral
GlobeNewsWire
2 months ago
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 130,117 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4's Compensation Committee of the Board of Directors.
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Charts implemented using Lightweight Charts™